“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

Traitement par inhibiteurs de tyrosine-kinase de 2 e génération chez les patients en échec de l’imatinib



Imatinib (IM) has dramatically improved the prognosis of chronic myeloid leukemia patients. Unfortunately, 30% of the patients will have to discontinue IM first-line treatment because of failure or intolerance. Second-generation tyrosine-kinase inhibitors, for example nilotinib, dasatinib, and the not yet licensed bosutinib, have been evaluated in phase II clinical trials in this setting. With a median follow-up of at least 24months, most of the responses are sustained while the safety profile of the three drugs appears acceptable but clearly different between the drugs. This review focuses on the available data regarding the efficacy and the safety profile of the three drugs.



OncologieSpringer Journals

Published: Oct 1, 2012

DOI: 10.1007/s10269-012-2214-1

Free Preview of First Page

Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.